29.22
+1.46%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mangalam Drugs and Organics
Its shares trade on NSE under the ticker MANGALAM.NS. It has been listed since 26 May 2005. In the fiscal year to 31 March 2025, it reported revenue of ₹3.18bn and net income of ₹67.2m. At that date it held total assets of ₹3.66bn and shareholders' equity of ₹1.49bn.
Mangalam Drugs & Organics Ltd. engages in the manufacture of drugs, medicines and allied products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-05-26. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. The company also focuses on specialty chemicals. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. Its API products include Acyclovir, Amodiaquine HCI, Artemether, Artesunate, Atazanavir Sulfate, Atorvastatin Calcium, Bisoprolol Fumarate and Furosemide. Its intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine, 2-Dibutylamino-1-Ethanol (DBA), 4,7- Dichloroquinoline, Ortho Phenoxy Methane Sulfonanilide, Tenofovir Alafenamide Base and Tenofovir Disoproxil Base. The company also offers specialty chemicals, such a L (+)-Menthol, 2,3 Dihydrophthalazine-1,4-dione, 4-Cynoethyl-2- Methyl Phenol. The firm has two multi-product manufacturing facilities located at Vapi, district Valsad, Gujarat.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 May 2005
- Employees
- 523
- Website
- mangalamdrugs.com ↗
Leadership
Pay as last reported
- Shri. Govardhan DhootExecutive Chairman of the Board, Managing Director, since 2021₹2.0m
- Mr. Ajay SamantChief Financial Officer₹2.7m
- Ms. Anuradha PandeyCompliance Officer, Company Secretary
- Shri. Brijmohan DhootWhole-time Director, since 2015₹600,000
- Mr. Rakesh MilwaniNon-Executive and Non-Independent Director
- Shri. Rukmesh DhandhaniaNon-Executive Independent Director₹36,000
- Smt. Nidhi MundadaNon-Executive Independent Director₹38,000
- Dr. Praveen SaxenaNon-Executive Independent Director₹20,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mangalam Drugs & Organics Ltd. manufactures Acyclovir and Artemether for global anti-malarial supply.
- The company operates two multi-product facilities in Vapi, Gujarat, supporting API and specialty chemical production.
- Mangalam Drugs & Organics Ltd. employs 523 full-time staff, ensuring stable operational capacity.
Weaknesses
- Mangalam Drugs & Organics Ltd. focuses on limited API products like Atorvastatin Calcium without broader diversification.
- The company's specialty chemicals include L (+)-Menthol but lack significant market presence in this segment.
- Mangalam Drugs & Organics Ltd. has no mention of digital transformation initiatives in its operations.
Opportunities
- Mangalam Drugs & Organics Ltd. can expand its Fight Malaria program to new global markets.
- The firm's API products like Atazanavir Sulfate may benefit from rising demand in HIV treatment.
- Mangalam Drugs & Organics Ltd. could leverage its Vapi facilities for increased specialty chemical exports.
Threats
- Mangalam Drugs & Organics Ltd. faces competition from larger pharmaceutical firms in API manufacturing.
- The company's reliance on specific APIs like Furosemide may lead to market volatility.
- Mangalam Drugs & Organics Ltd. operates in a highly regulated Health Care sector with strict compliance demands.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.